Oral Abstract Session
Diabetic Kidney Disease - Clinical: Novel Insights into Precision Medicine
October 24, 2024 | 04:30 PM - 06:00 PM
Location: Room 33, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Diabetic Kidney Disease
Moderators
Presentations
- Finerenone in Patients with Type 2 Diabetes and CKD by SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists Receptor Agonist Use: A FIDELITY Analysis
04:30 PM - 04:40 PM
- Urinary Clusterin as a Pharmacodynamic Response Biomarker for the Endothelin Receptor Antagonist Atrasentan
04:40 PM - 04:50 PM
- Ephrin Signaling and the Development of Early Progressive Kidney Function Decline
04:50 PM - 05:00 PM
- Advancing KidneyIntelX Precision Medicine Platform in CKD
05:00 PM - 05:10 PM
- Identification of Circulating Microbial DNA and Its Correlation in Patients with Diabetic Kidney Disease
05:10 PM - 05:20 PM
- Autophagy-Related Gene Expression in Diabetes and CKD
05:20 PM - 05:30 PM
- Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of SGLT2 Inhibition: Results from the CANVAS and CREDENCE Trials
05:30 PM - 05:40 PM
- Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of EASE-2 and -3
05:40 PM - 05:50 PM
- Glycemic Patterns of Peritoneal Dialysis Patients Assessed by Continuous Glucose Monitoring
05:50 PM - 06:00 PM